If Big Pharma didn't already have enough to worry about, with patent cliffs, drug price investigations and reluctant payers, it now will have to face the onslaught of a large, well-funded company trying to create hybrid pharma and food products company that would treat conditions from stomach disorders to Alzheimer's disease.
Last month, names like Sanofi, Pfizer, Abbott and Takeda were flying around as potential suitors for Mexico-based Representaciones e Investigaciones Medicas, aka Rimsa. But it's Teva that's emerged victorious in the field.
Abbott Laboratories wlll expand its manufacturing, as well as other operations, in India, though a dollar amount was not given by the pharmaceutical giant.
Lately, Latin America has been leading the growth ranks for Merck KGaA's consumer health unit. And that's not set to change anytime soon, its leader says.
The Indian Drug Manufacturers' Association says the country's pharmaceutical contract manufacturing industry is growing at 20%.
Novartis has stood by its commitment to emerging markets even in rocky times. And now, it's furthering that commitment with an access initiative for low-income countries.
Chinese contract drug developer ShangPharma is planning to invest $60 million to build a biologics research and manufacturing outpost near its home base in Shanghai.
Asia's largest vaccinemaker just made a play that could affect the race for a vaccine protecting against dengue fever, a common affliction that has a big impact in the region.
GE Healthcare has staked a major claim in a field that's not well tended--the development of affordable medical technologies to improve health outcomes in the emerging markets. It's creating a devoted business called Sustainable Healthcare Solutions out of a combination of its operations in India, South Asia, Africa and Southeast Asia dedicated to serving 70 markets--and investing $300 million to back the effort.
The middle class in emerging market countries wants diagnostics--and Minneapolis, MN-based Ativa Medical plans to bring it to them via a point-of-care, micro lab designed for the physician office. The startup has secured a $15 million Series B round that's intended to support gaining FDA approval for its micro lab and preparing for commercial launch.